New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice - 29/08/11
Doi : 10.1067/S0190-9622(03)01149-6
Mappa
 | Disclosure: Dr Callen has been an investigator on a study of etanercept for psoriatic arthritis and has received honoraria either directly or indirectly from Amgen (formerly Immunex), Genentech, Biogen, Centocor, Roche, Novartis, Doak Dermatologics, 3M, and Dermik. He has also served as a consultant for Biogen, Amgen (formerly Immunex), Doak Dermatologics, ICN, 3M, and Centocor. He is the Chair of the Ad Hoc Task Force: Psoriasis Education Initiative of the American Academy of Dermatology and was the Chair of the Psoriasis Therapies Educational Summit that was held in Louisville, Ky on November 2-3, 2002. |
© 2003
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 49 - N° 2
P. 351-356 - agosto 2003 Ritorno al numero
Articolo precedente
- Bullous scabies
- Rana Kamal Ahmad Shahab, Daniel Sukang Loo
- Newer antifungal agents
- Michael Bigby
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?